Synthesis of novel organohalogen chalcone derivatives and screening of their molecular docking study and some enzymes inhibition effects

Abstract

Chalcones and their derivatives are increasing attention due to numerous biochemical and pharmacological applications. In this study, a series of novel organohalogen chalcone derivatives (5–12) were tested towards α-glycosidase (α-Gly), acetylcholinesterase (AChE) human carbonic anhydrase I (hCA I), and carbonic anhydrase II (hCA II) enzymes. These compounds (5–12) showed Kis in ranging of 16.24–40.96 nM on hCA I, 29.61–67.15 nM on hCA II, 1.21–4.39 nM on AChE and 12.54–35.22 nM on α-glycosidase. The novel organohalogen chalcone derivatives (5–12) had effective inhibition profiles against all tested metabolic enzymes. Also, because of the enzyme inhibitory effects of the compounds (5–12), they have the potential of drug candidates to treat of some diseases including epilepsy, glaucoma, type-2 diabetes mellitus (T2DM), Alzheimer’s disease (AD), and leukemia. Also, the chalcone derivatives with best inhibition score docked into the active site of indicated metabolic enzymes receptors. Bromobenzyle and chlorophenyl moieties of chalcone derivatives contribute to their inhibitor properties on the enzymes.